Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20$53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to ...